Revance Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Revance Therapeutics (RVNC) Prices 5.34M Offering of Common Stock at $31/Share
December 7, 2017 8:34 AM ESTRevance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions (Revance or the Company), today announced the pricing of an underwritten public offering of 5,338,709 shares of its common stock at a price to the public of $31.00 per share. In the offering, the Company will issue and sell 4,838,709 shares and certain stockholders of the Company (the Selling Stockholders) will sell 500,000 shares. Revance and the Selling Stockholders have granted the underwriters a 30-day option to purchase up to an... More
